https://www.asm.org/modules/mod_image_show_gk4/cache/mSphere Direct herogk-is-651.pnglink
https://www.asm.org/modules/mod_image_show_gk4/cache/Podcast Hero Banner3gk-is-651.pnglink
https://www.asm.org/modules/mod_image_show_gk4/cache/Microbe Online Program Plannergk-is-651.pnglink
https://www.asm.org/modules/mod_image_show_gk4/cache/AAAS Fellows Bannergk-is-651.jpglink
https://www.asm.org/modules/mod_image_show_gk4/cache/Read New JMBE Bannergk-is-651.jpglink
0 1 2 3 4
Progress bar
22-01-2017mSphere Direct
22-01-2017Podcast banner
22-01-2017AAAS Fellows
22-01-2017Read new JMBE
Become a member today!
JOIN/RENEW
Submit to an ASM Journal
SUBMIT
Attend ASM Biothreats Meeting
REGISTER

 

Dr. Hazuda's research on the HIV-1 integrase enzyme catalyzed the identification of viral integration inhibitors, the validation of this mechanism in vivo, and the understanding of mechanisms of resistance. These accomplishments resulted in the development and approval of raltegravir (tradename ISENTRESS), the first integrase inhibitor licensed for treatment of HIV-1 infection.

TPL_asm2013_SEARCH

91033